Q-omics provides the consensus-scored ZC3H12A profile across patient tissues and cancer cell-line models. ZC3H12A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZC3H12A is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZC3H12A RNA expression shows 18,556 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where ZC3H12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H12A survival associations across molecular data types. ZC3H12A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H12A RNA expression–survival associations across cancer types. High ZC3H12A expression shows unfavorable associations in ACC, KIRC, LGG and UVM, but favorable associations in SKCM and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZC3H12A RNA expression.
This table summarizes ZC3H12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H12A shows lower tumor expression in KICH, BRCA and BLCA and higher tumor expression in COAD, PAAD and ESCA. The KICH box plot shows higher ZC3H12A RNA expression in normal versus tumor tissue (log2 FC = −2.301, t-test p < 0.001).
This table shows molecular features associated with ZC3H12A in patient tissues and cancer cell lines. In patient samples, ZC3H12A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
